Report Code: A03262 | Aug 2017 | Pages: 140 | ||
Tables: 39 | Charts: 54 |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Uk Ivd Market
Request Now !UK IVD Market is accounted for $2,148 million in 2016, and is estimated to reach $3,127 million by 2023, growing at a CAGR of 5.4% during the analysis period (2017-2023). In vitro diagnostics are the medical devices, which are utilized to determine the diseased conditions. They require biological samples such as blood, urine, stool, tissues, and other body fluids, to detect diseases, conditions, and infections. These tests are easy to perform and offer accurate results. In addition, IVD has wide range of application in diagnosis of various diseases such as, infectious diseases, diabetes, cancer, cardiology diseases, autoimmune diseases, nephrology, and HIV/AIDS.
High rate in incidences of chronic diseases, advancement in IVD techniques, and rise in demand for minimally invasive techniques are expected to fuel the market growth during the analysis period. However, strict reimbursement policies and stringent government regulation in terms of product approval restrict the growth of the market.
UK IVD Market Segmentation
Segment Review
Based on product type, the market is categorized into reagents, instruments, and software & services. The reagent segment accounted for the highest market share in 2017, and the software and services is expected to grow at the highest growth rate during the forecast period. The growth of the reagent market is attributed to the recent introduction of new novel reagents and wide availability of effective and cost-efficient reagents. On the basis of technique, the immunodiagnostics segment captured the highest market share in 2016, owing to the increase in demand of personalized medicines. On the basis of application, infectious diseases segment captured the highest market share in 2016, due to rise in prevalence of infectious diseases and growth in preventive healthcare awareness among the population. Based on end users, the standalone laboratory segment captured the highest market share in 2016, primarily due to non-availability of complex tests in hospitals and commercial clinics.
Top Investment Pockets
Increase an Incidences of Chronic Diseases
IVD market in the UK is in its growth phase due to increase in incidence of chronic diseases such as arthritis, cancer, cardiovascular diseases, neurodegenerative disorder, and diabetes. According to WHO, 75% of the total population suffers from one chronic condition, while 50% with two or more conditions. Thus, high rate of such diseases increases the demand for the IVD market.
Emergence of Minimally Invasive Technologies
IVD refers to diagnosis of disease caused by infection or disorder in laboratory conditions. Normally urine, saliva, blood, and others are used for analysis by minimally invasive technology. These minimally invasive techniques require a smallest possible incision in the body followed by the insertion of a long thin tube with a small camera. The images are projected on the monitors in the operating rooms to provide surgeons a magnified view of the internal organs and help detect and cure the disease. Moreover, advancement in minimally invasive techniques increase the demand for IVD market due to less incisional procedures. In this technology penetration process are being replaced by radiation to destroy the target tissue through high intensity of ultrasound beam.
Key Market Benefits:
UK IVD Market Report Highlights
Aspects | Details |
---|---|
By Product Type |
|
By TECHNIQUE |
|
By APPLICATION |
|
By END USERS |
|
Key Market Players | SYSMEX CORPORATION, BAYER AG, ALERE INC, BIO-RAD LABORATORIES, F. HOFFMANN-LA ROCHE AG, DANAHER CORPORATION, BIOMERIEUX, BECTON DICKINSON AND COMPANY, THERMO FISHER SCIENTIFIC INC, JOHNSON & JOHNSON |
CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 KEY BENEFITS
1.3 KEY MARKET SEGMENTS
1.4 RESEARCH METHODOLOGY
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1 MARKET DEFINITION AND SCOPE
3.2 KEY FINDINGS
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 PORTER’S FIVE FORCES ANALYSIS
3.3.1 Bargaining power of suppliers
3.3.2 Bargaining power of buyers
3.3.3 Threat of new entrants
3.3.4 Threat of substitute
3.3.5 Competitive rivalry
3.4 MARKET SHARE ANALYSIS, 2016
3.5 MARKET DYNAMICS
3.5.1 Drivers
3.5.1.1 Increasing incidence of chronic and infectious diseases
3.5.1.2 Technological advancements in IVD
3.5.1.3 Emergence of minimal invasive technologies
3.5.1.4 Increasing government expenditures on healthcare
3.5.1.5 Increase in popularity of personalized medicine approach
3.5.2 Restraint
3.5.2.1 Unclear reimbursement policies
3.5.2.2 Stringent regulatory policies
3.5.3 Opportunity
3.5.3.1 Potential opportunities for outsourcing
3.5.3.2 Convergence of new technologies
CHAPTER 4 IVD MARKET, BY PRODUCT TYPE
4.1 OVERVIEW
4.1.1 Market size and forecast
4.2 REAGENTS
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 INSTRUMENTS
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 SOFTWARE AND SERVICES
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
CHAPTER 5 IVD MARKET, BY TECHNIQUE
5.1 OVERVIEW
5.1.1 Market size and forecast
5.2 IMMUNODIAGNOSTICS
5.2.1 Key market trends
5.2.2 Key growth factors and opportunities
5.2.3 Market size and forecast
5.2.4 Enzyme-linked immunosorbent assay (ELISA)
5.2.4.1 Market size and forecast
5.2.4.2 Chemiluminescence immunoassay (CLIA)
5.2.4.2.1 Market size and forecast
5.2.4.3 Fluorescence immunoassay (FIA)
5.2.4.3.1 Market size and forecast
5.2.4.4 Colorimetric immunoassay (CI)
5.2.4.4.1 Market size and forecast
5.2.5 Rapid tests
5.2.5.1 Market size and forecast
5.2.6 Enzyme-linked immunospot (ELISPOT)
5.2.6.1 Market size and forecast
5.2.7 Radioimmunoassay (RIA)
5.2.7.1 Market size and forecast
5.2.8 Western blot
5.2.8.1 Market size and forecast
5.3 BLOOD TESTING
5.3.1 Key market trends
5.3.2 Key growth factors and opportunities
5.3.3 Market size and forecast
5.4 MOLECULAR DIAGNOSTICS
5.4.1 Key market trends
5.4.2 Key growth factors and opportunities
5.4.3 Market size and forecast
5.4.4 Polymerize chain reaction (PCR)
5.4.4.1 Market size and forecast
5.4.5 Isothermal nucleic acid technology (INAAT)
5.4.5.1 Market size and forecast
5.4.6 Hybridization
5.4.6.1 Market size and forecast
5.4.7 DNA diagnostics
5.4.7.1 Market size and forecast
5.4.8 Microarray
5.4.8.1 Market size and forecast
5.4.9 Others
5.4.9.1 Market size and forecast
5.5 TISSUE DIAGNOSTICS
5.5.1 Key market trends
5.5.2 Key growth factors and opportunities
5.5.3 Market size and forecast
5.6 CLINICAL CHEMISTRY
5.6.1 Key market trends
5.6.2 Key growth factors and opportunities
5.6.3 Market size and forecast
5.6.4 Basic metabolic panel
5.6.4.1 Market size and forecast
5.6.5 Liver panel
5.6.5.1 Market size and forecast
5.6.6 Renal profile
5.6.6.1 Market size and forecast
5.6.7 Lipid profile
5.6.7.1 Market size and forecast
5.6.8 Thyroid function panel
5.6.8.1 Market size and forecast
5.6.9 Electrolyte panel
5.6.9.1 Market size and forecast
5.6.10 Speciality chemicals
5.6.10.1 Market size and forecast
5.7 OTHER IVD TECHNIQUES
5.7.1 Key market trends
5.7.2 Key growth factors and opportunities
5.7.3 Market size and forecast
CHAPTER 6 IVD MARKET, BY APPLICATION
6.1 INFECTIOUS DISEASES
6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast
6.2 CANCER
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.3 CARDIAC DISEASES
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Market size and forecast
6.4 IMMUNE SYSTEM DISORDERS
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.5 NEPHROLOGICAL DISEASES
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.6 GASTROINTESTINAL DISEASES
6.6.1 Key market trends
6.6.2 Key growth factors and opportunities
6.6.3 Market size and forecast
6.7 OTHERS INDICATIONS
6.7.1 Key market trends
6.7.2 Key growth factors and opportunities
6.7.3 Market size and forecast
CHAPTER 7 IVD MARKET BY END USERS
7.1 STANDALONE LABORATORIES
7.1.1 Market size and forecast
7.2 HOSPITALS
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.3 ACADEMIC AND MEDICAL SCHOOLS
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.4 POINT OF CARE TESTING
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
7.5 OTHERS END-USER
7.5.1 Key market trends
7.5.2 Key growth factors and opportunities
7.5.3 Market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1 THERMO FISHER SCIENTIFIC INC.
8.1.1 Company overview
8.1.2 Business performance
8.1.3 Key strategies and development
8.2 ALERE INC.
8.2.1 Company overview
8.2.2 Business performance
8.2.3 Key strategies and developments
8.3 BIOMERIEUX
8.3.1 Company overview
8.3.2 Business performance
8.3.3 Key strategies and developments
8.4 DANAHER CORPORATION
8.4.1 Company overview
8.4.2 Business performance
8.4.3 Key strategies and development
8.5 F. HOFFMANN-LA ROCHE AG
8.5.1 Company overview
8.5.2 Business performance
8.5.3 Key strategies and developments
8.6 BECTON DICKINSON AND COMPANY
8.6.1 Company overview
8.6.2 Business performance
8.6.3 Key strategies and development
8.7 BIO-RAD LABORATORIES
8.7.1 Company overview
8.7.2 Business performance
8.7.3 Key strategies and developments
8.8 BAYER AG
8.8.1 Company overview
8.8.2 Business performance
8.8.3 Key strategies and development
8.9 SYSMEX CORPORATION
8.9.1 Company overview
8.9.2 Business performance
8.9.3 Key strategies and developments
8.10 JOHNSON & JOHNSON
8.10.1 Company overview
8.10.2 Business performance
8.10.3 Key strategies and development
List of Figures
FIGURE 1 MARKET SEGMENTATION
FIGURE 2 TOP INVESTMENT POCKETS
FIGURE 3 TOP WINNING STRATEGIES, 2014-2016 (%)
FIGURE 4 TOP WINNING STRATEGIES: NATURE AND TYPE, 2014-2016
FIGURE 5 PORTER’S FIVE FORCES ANALYSIS
FIGURE 6 MARKET SHARE ANALYSIS: IVD MARKET, 2016
FIGURE 7 UK CHEMILUMINESCENCE IMMUNOASSAY (CLISA) MARKET, 2016-2023 ($MILLION)
FIGURE 8 UK FLUORESCENCE IMMUNOASSAY (FIA) MARKET, 2016-2023 ($MILLION)
FIGURE 9 UK COLORIMETRIC IMMUNOASSAY (CI) MARKET, 2016-2023 ($MILLION)
FIGURE 10 UK RAPID TESTS MARKET, 2016-2023 ($MILLION)
FIGURE 11 UK ENZYME-LINKED IMMUNOSPOT (ELISPOT) MARKET, 2016-2023 ($MILLION)
FIGURE 12 UK RADIOIMMUNOASSAY (RIA) MARKET, 2016-2023 ($MILLION)
FIGURE 13 UK WESTERN BLOT TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 14 UK POLYMERIZE CHAIN REACTION PCR MARKET, 2016-2023 ($MILLION)
FIGURE 15 UK ISOTHERMAL NUCLEIC ACID TECHNOLOGY (INAAT) MARKET, 2016-2023 ($MILLION)
FIGURE 16 UK HYBRIDIZATION MARKET, 2016-2023 ($MILLION)
FIGURE 17 UK DNA DIAGNOSTICS MARKET, 2016-2023 ($MILLION)
FIGURE 18 UK MICROARRAY MARKET, 2016-2023 ($MILLION)
FIGURE 19 UK OTHER MOLECULAR DIAGNOSTIC TECHNIQUE MARKET, 2016-2023 ($MILLION)
FIGURE 20 UK BASIC METABOLIC PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 21 UK LIVER PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 22 UK RENAL PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 23 UK LIPID PROFILE MARKET, 2016-2023 ($MILLION)
FIGURE 24 UK THYROID FUNCTION PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 25 UK ELECTROLYTE PANEL MARKET, 2016-2023 ($MILLION)
FIGURE 26 UK SPECIALITY CHEMICALS MARKET, 2016-2023 ($MILLION)
FIGURE 27 THERMO FISHER SCIENTIFIC INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 28 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 29 THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 30 ALERE INC.: REVENUE, 2014-2016, ($MILLION)
FIGURE 31 ALERE INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 32 ALERE INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 33 BIOMERIEUX REVENUE: 2014-2016 ($MILLION)
FIGURE 34 BIOMERIEUX: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 35 BIOMERIEUX: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 36 DANAHER CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 37 DANAHER CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 38 DANAHER CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 39 ROCHE DIAGNOSTICS: REVENUE, 2014-2016 ($MILLION)
FIGURE 40 ROCHE DIAGNOSTICS: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 41 BECTON, DICKINSON AND COMPANY: REVENUE, 2014-2016 ($MILLION)
FIGURE 42 BECTON DICKINSON AND COMPANY: REVENUES BY SEGMENT (%) (2016)
FIGURE 43 BECTON DICKINSON AND COMPANY: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 44 BIO-RAD LABORATORIES: REVENUE, 2014-2016 ($MILLION)
FIGURE 45 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 46 BIO RAD LABORATORIES, INC.: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 47 BAYER AG: REVENUE, 2014-2016 ($MILLION)
FIGURE 48 BAYER AG: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 49 SYSMEX CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 50 SYSMEX CORPORATION: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 51 SYSMEX CORPORATION: REVENUE SHARE BY GEOGRAPHY, (2016) (%)
FIGURE 52 JOHNSON & JOHSNON: REVENUE, 2014 - 2016 ($MILLION)
FIGURE 53 JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENTS, (2016) (%)
FIGURE 54 JOHNSON & JOHNSON: REVENUE SHARE BY GEOGRAPHY, (%)(2016)
List of Tables
TABLE 1 INCIDENCE OF DISEASES
TABLE 2 UK IVD MARKET, BY PRODUCT TYPE, 2016-2023 ($MILLION)
TABLE 3 UK IVD REAGENTS MARKET, 2016-2023 ($MILLION)
TABLE 4 UK IVD INSTRUMENTS MARKET, 2016-2023 ($MILLION)
TABLE 5 UK IVD SOFTWARE & SERVICES MARKET, 2016-2023 ($MILLION)
TABLE 6 UK IVD MARKET BY TECHNIQUE, 2016-2023 ($MILLION)
TABLE 7 UK IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, BY TYPES, 2016-2023 ($MILLION)
TABLE 8 UK IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET, 2016-2023 ($MILLION)
TABLE 9 UK IVD IMMUNODIAGNOSTIC TECHNIQUE MARKET FOR ELISA, BY TYPES, 2016-2023 ($MILLION)
TABLE 10 UK IVD BLOOD TESTING TECHNIQUE MARKET, 2016-2023 ($MILLION)
TABLE 11 UK IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 12 UK IVD MOLECULAR DIAGNOSTICS TECHNIQUE MARKET, 2016-2023 ($MILLION)
TABLE 13 UK IVD TISSUE DIAGNOSTICS TECHNIQUE MARKET, 2016-2023, ($MILLION)
TABLE 14 UK IVD CLINICAL CHEMISTRY TECHNIQUE MARKET, 2016-2023 ($MILLION)
TABLE 15 UK OTHER IVD TECHNIQUES MARKET, 2016-2023, ($MILLION)
TABLE 16 UK IVD MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 17 UK IVD INFECTIOUS DISEASES MARKET, 2016-2023 ($MILLION)
TABLE 18 UK IVD CANCER MARKET, 2016-2023 ($MILLION)
TABLE 19 UK IVD CARDIAC DISEASES MARKET, 2016-2023 ($MILLION)
TABLE 20 UK IVD IMMUNE SYSTEM DISORDER MARKET, 2016-2023 ($MILLION)
TABLE 21 UK IVD NEPHROLOGICAL DISEASES MARKET, 2016-2023, ($MILLION)
TABLE 22 UK IVD GASTROINTESTINAL DISEASES MARKET, 2016-2023 ($MILLION)
TABLE 23 UK IVD OTHER INDICATION MARKET, 2016-2023 ($MILLION)
TABLE 24 UK IVD MARKET, BY END USER, 2016-2023, ($MILLION)
TABLE 25 UK IVD STANDALONE LABORATORIES MARKET, 2016-2023 ($MILLION)
TABLE 26 UK IVD HOSPITALS MARKET, 2016-2023 ($MILLION)
TABLE 27 UK IVD ACADEMIC AND MEDICAL SCHOOLS MARKET, 2016-2023 ($MILLION)
TABLE 28 UK IVD POINT OF CARE MARKET, 2016-2023 ($MILLION)
TABLE 29 UK IVD OTHER END-USER MARKET, 2016-2023 ($MILLION)
TABLE 30 THERMO FISHER SCIENTIFIC INC. COMPANY SNAPSHOT
TABLE 31 ALERE INC. COMPANY SNAPSHOT
TABLE 32 BIOMERIEUX COMPANY SNAPSHOT
TABLE 33 DANAHER CORPORATION COMPANY SNAPSHOT
TABLE 34 ROCHE DIAGNOSTICS COMPANY SNAPSHOT
TABLE 35 BECTON DICKINSON AND COMPANY SNAPSHOT
TABLE 36 BIO-RAD LABORATORIES, INC. COMAPNY SNAPSHOT
TABLE 37 BAYER AG COMPANY SNAPSHOT
TABLE 38 SYSMEX CORPORATION COMPANY SNAPSHOT
TABLE 39 JOHNSON & JOHNSON PVT LTD. COMPANY SNAPSHOT
In vitro diagnostics (IVD) refers to diagnosis of diseases caused by infection or disorder in laboratory conditions. Biological samples such as, urine, saliva, such as blood, stool, urine, tissues, and other body fluids are utilized for analysis of several disease. IVD tests analyze biological samples using technologies such as polymerase chain reaction, microarray techniques, sequencing technology, and mass spectrometry for sample test preparation.
The UK IVD market is growing due to increase in government expenditure in healthcare sector, rise in incidences for chronic diseases, and growth in demand for non-invasive techniques. In addition, rise in prevalence of chronic and infectious diseases such as cancer, tuberculosis, diabetes, HIV, and others also drive the UK IVD market. In addition, government initiatives for the improvement of healthcare sector and rise in technological advancement is expected to provide high growth opportunities for the IVD market.
Major companies involved in the UK IVD market are Thermo Fisher Scientific Inc., Alere Inc., Biomerieux, Danaher Corporation, F. Hoffmann-La Roche AG, Becton Dickinson and Company, Bio-Rad Laboratories, Bayer AG, Sysmex Corporation, and Johnson & Johnson.
Start reading instantly.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers